Apple posts strong Q4 results, driven by robust iPhone 17 sales and growth in services, despite supply shortages and regional disparities.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Altria's Q3 earnings beat estimates, but shares fell on weak outlook and persistent category challenges.
Apple posts strong Q4 results, driven by robust iPhone 17 sales and growth in services, despite supply shortages and regional disparities.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Altria's Q3 earnings beat estimates, but shares fell on weak outlook and persistent category challenges.